![Neil Kirby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Neil Kirby
Direktor/Vorstandsmitglied bei Orphan Technologies Ltd.
Aktive Positionen von Neil Kirby
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Orphan Technologies Ltd.
![]() Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Neil Kirby
Ehemalige bekannte Positionen von Neil Kirby
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - | - |
Edimer Pharmaceuticals, Inc.
![]() Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 01.01.2009 | - |
Vorstandsvorsitzender | 15.09.2009 | - | |
Präsident | 15.09.2009 | - | |
Treasurer | 01.01.2009 | - | |
Stromedix, Inc.
![]() Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Genetics Institute LLC
![]() Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - | - |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | General Counsel | - | - |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | 01.01.2002 | - |
Ausbildung von Neil Kirby
University of London | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Schweiz | 3 |
Vereinigtes Königreich | 2 |
Operativ
Corporate Officer/Principal | 3 |
Director/Board Member | 3 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 7 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
Private Unternehmen | 6 |
---|---|
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Genetics Institute LLC
![]() Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Stromedix, Inc.
![]() Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Edimer Pharmaceuticals, Inc.
![]() Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Orphan Technologies Ltd.
![]() Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Health Technology |
- Börse
- Insiders
- Neil Kirby
- Erfahrung